Analysts Issue Forecasts for TRVI FY2025 Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Trevi Therapeutics in a note issued to investors on Tuesday, July 1st. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will earn ($0.39) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $25.00 price objective on the stock. The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.49) per share. Cantor Fitzgerald also issued estimates for Trevi Therapeutics' FY2026 earnings at ($0.47) EPS.

Several other research analysts also recently issued reports on TRVI. Needham & Company LLC reiterated a "buy" rating and issued a $24.00 target price on shares of Trevi Therapeutics in a research note on Tuesday, May 20th. Oppenheimer reaffirmed an "outperform" rating on shares of Trevi Therapeutics in a research report on Monday, June 2nd. D. Boral Capital restated a "buy" rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research report on Monday, June 2nd. HC Wainwright assumed coverage on Trevi Therapeutics in a research report on Wednesday, May 28th. They issued a "buy" rating and a $21.00 price objective on the stock. Finally, B. Riley restated a "buy" rating and issued a $20.00 price objective (up from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Trevi Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $20.88.

Trevi Therapeutics Trading Down 1.4%

Shares of NASDAQ TRVI traded down $0.08 during midday trading on Thursday, hitting $5.90. The stock had a trading volume of 993,025 shares, compared to its average volume of 1,425,886. The business's 50 day moving average is $6.28 and its 200-day moving average is $5.39. Trevi Therapeutics has a 52 week low of $2.36 and a 52 week high of $7.48.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.04.

Institutional Investors Weigh In On Trevi Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Frazier Life Sciences Management L.P. lifted its position in shares of Trevi Therapeutics by 44.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company's stock worth $43,939,000 after buying an additional 3,283,684 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Trevi Therapeutics in the fourth quarter worth about $17,099,000. Vanguard Group Inc. lifted its position in shares of Trevi Therapeutics by 9.4% in the first quarter. Vanguard Group Inc. now owns 3,838,032 shares of the company's stock worth $24,141,000 after buying an additional 328,819 shares in the last quarter. Vivo Capital LLC lifted its position in shares of Trevi Therapeutics by 116.3% in the fourth quarter. Vivo Capital LLC now owns 3,487,903 shares of the company's stock worth $14,370,000 after buying an additional 1,875,000 shares in the last quarter. Finally, MPM Bioimpact LLC increased its stake in Trevi Therapeutics by 10.8% during the first quarter. MPM Bioimpact LLC now owns 3,428,366 shares of the company's stock worth $21,564,000 after acquiring an additional 333,470 shares during the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.